Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

NCT06851806 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus (RSV)

Interventions

DRUG: Palivizumab 15 mg/kg

Sponsor

AstraZeneca